Lovenox (enoxaparin sodium) Injection

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved February 1998

Specific Treatments:

prevention of blood clots following hip-replacement surgery

General Information

Lovenox (enoxaparin sodium) Injection has been approved for the extended prevention of deep-vein thrombosis (DVT) following hip replacement surgery. It was previously approved for use in a hospital setting, and is the first low-molecular-weight heparin to be approved for once a day at home use.

Clinical Results

In clinical studies, patients discharged for the hospital without signs of venous thromboembolic disease received either a three-week regimen of Lovenox, or placebo. Results demonstrated that the incidence of DVT during the three-week period was significantly lower in the Lovenox patients, 7% compared to 20% for placebo.

Side Effects

Nine percent of patients reported an incidence of injection-site hematoma (bruising).

Mechanism of Action

Lovenox (enoxaparin sodium) is an antithrombotic agent known as a low-molecular-weight heparin.